跳至主要内容
临床试验/ACTRN12618000566235
ACTRN12618000566235进行中(未招募)2 期

Ablative Stereotactic Radiotherapy as an alternative to systemic treatment in men with oligometastatic prostate cancer and controlled primary disease. A prospective Phase II study measuring toxicity, disease control and freedom from escalation in systemic therapy

Integrated Clinical Oncology Network Pty Ltd (ICON)0 个研究点目标入组 208 人开始时间: 2018年4月13日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
208

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
Male

入选标准

  • Histologically confirmed diagnosis of prostate cancer.
  • - Biochemical relapses of prostate cancer following radical local treatment.
  • - Males aged 18 years to 80 years inclusive.
  • - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • - N1 and M1 a/b disease on imaging, with a combined maximum of five synchronous lesions
  • - Exclusion of local relapse.
  • - Metastases suitable for ablative radiotherapy

排除标准

  • - No prior palliative radiotherapy (definitive radiotherapy as part of initial management is allowed).
  • - Active local disease on clinical examination.

研究者

发起方
Integrated Clinical Oncology Network Pty Ltd (ICON)

相似试验